Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-11 (CLDN11)
- Target
- CLDN11
- Molecular classification
- Tight junction protein, Integral membrane protein, Structural molecule, Other (component of myelin sheath)
01
Overview
Claudin-11 (CLDN11) is an integral membrane protein belonging to the claudin family, which forms the backbone of tight junction strands in multiple organ systems. It is a major structural component of myelin in the central nervous system, where it is essential for the assembly of specialized paracellular barriers and the regulation of ion flow and electrical resistance, thereby enabling normal nerve conduction. In the testis, claudin-11 is indispensable for blood-testis barrier formation by Sertoli cells, crucial for spermatogenesis and immune privilege. Functional loss or mutation of CLDN11 causes syndromes such as hypomyelinating leukodystrophy (HLD22), deafness, and infertility. Claudin-11 also interacts with other proteins to regulate oligodendrocyte proliferation and migration, and emerging data suggest it may serve as an autoantigen in autoimmune demyelinating disease[1][2][3][4][5][7].
- Other names
- Oligodendrocyte-specific proteinOSPOTMHLD22Claudin 11Oligodendrocyte transmembrane protein
02
Mechanism of action
no approved or clinically established drugs targeting claudin-11; mechanism would be modulation of tight junction assembly/function if targeted
03
Biological functions
Formation and maintenance of tight junctionsRegulation of paracellular barrier in epithelial/endothelial cellsRegulation of ion diffusion and electrical resistance in CNS myelinProliferation and migration of oligodendrocytesOrganization of the blood-testis barrierMaintenance of Sertoli cell polarity
04
Disease associations
Neurodegenerative disease (e.g. hypomyelinating leukodystrophy, HLD22)Auditory dysfunction/deafnessMale infertility (blood-testis barrier disruption, spermatogenesis failure)Potential role as an autoantigen in autoimmune demyelinating diseases (e.g. multiple sclerosis models)Possible contribution to neuropsychiatric disorders via myelin dysfunction
05
Safety considerations
Targeting claudin-11 may risk compromising CNS myelin function, leading to neurological deficitsDisruption of blood-testis barrier could lead to infertility and autoimmune reactions against germ cellsPotential hearing loss if function disrupted
06
Biomarkers
Claudin-11 protein levels (for hypomyelinating leukodystrophy, CNS myelin integrity, and possibly for blood-testis barrier function)
Beyond the preview
Go deeper on Claudin-11 (CLDN11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin-11 (CLDN11).